All articles tagged with #bioethics
Cathy Tie, founder of Origin Genomics, argues that editing human embryos to prevent hereditary diseases is a moral imperative, despite current U.S. bans and safety concerns. While critics warn of eugenics and off-target risks, proponents cite new precise editing tools and patient demand for alternatives to IVF screening.
Cathy Tie, CEO of New York-based Origin Genomics, is testing AI-assisted gene editors on human embryos to prevent inherited diseases like familial adenomatous polyposis. While the company aims to prove safety to eventually lift U.S. legal bans on embryo editing, critics warn of 'designer babies' and unregulated overseas clinics. Tie argues that pursuing this technology is ethical given the suffering of affected families, despite current prohibitions and safety concerns.
A Dutch government report has revealed that the first child euthanized under the Netherlands' 2024 expansion of assisted-dying laws was a 24-month-old infant with severe, untreatable brain damage. The child, born prematurely at 26 weeks, suffered from cerebral palsy, epilepsy, and visual impairment. A medical review committee ruled the procedure lawful, though the case has sparked intense debate over the ethics of ending a child's life versus providing palliative care.
Researchers transplanted human brain tissue into newborn mice engineered to lack a cortical region. Within 2–3 months the graft expanded to fill more than 90% of the empty brain space and formed extensive neural connections, including von Economo-like neurons, wiring into the animals’ nervous systems. Described as the most extensive human-brain-cell integration in an animal to date, the work provides a powerful platform to study human neurodevelopment and test therapies for developmental brain disorders, while undergoing ethical oversight and without increasing the rodents’ intelligence.
The deaths of two children in China after receiving CRISPR-based therapies have renewed concerns among scientists about the safety and ethics of delivering gene-editing medicines with viral vectors, prompting renewed calls in the US for tighter standards and oversight.
Researchers transplanted human iPS-derived immature cells into a mouse kidney pouch, where they self-organized into early sperm-supporting structures and developed into spermatogonia after six months. While this marks progress toward lab-made sperm, the cells did not mature yet, signaling further hurdles. The work offers a new avenue to study early human sperm development and infertility, though clinical applications are far off and raise ethical questions about future reproductive technologies.
Scientists announced on July 2, 2026 that they created SpudCell, the first synthetic cell built from purified, nonliving components. While it can feed, grow, replicate genetic material and undergo a cell-like division, it is not autonomous: it relies on laboratory conditions and ongoing input of molecular machinery, and it cannot reproduce indefinitely. The milestone helps researchers study core cellular processes—membranes, gene expression, energy use, and growth—while offering potential safe, simplified platforms for disease research, drug delivery, and environmental sensing. It also highlights ongoing debates about what constitutes life, and underscores the need for safety, governance, and ethical oversight in synthetic biology.
Henry Wismayer surveys the Mars dream—from enthusiasts at the British Interplanetary Society to advocates like Zubrin and SpaceX—against sobering biology, physics, and governance challenges. He reports that Mars’ radiation, low gravity, extreme temperatures, and pervasive dust threaten human health and reproduction; the Outer Space Treaty and Artemis Accords offer little enforcement, raising questions about sovereignty and safety. Skeptics warn against turning Mars into a fragile, centralized frontier, while proponents call for cautious Moon-first testing and phased exploration. The piece concludes that while the allure remains, a careful, wait-and-go-big approach is prudent before any permanent Martian settlement is attempted.
The United States confirmed a natural incursion of the New World screwworm in Texas cattle—the first since 1982—after decades of eradicating the pest with mass releases of sterile male flies. Facing potential billions in economic impact from livestock losses, the USDA is funding a $750 million facility in Texas to produce about 300 million sterile screwworms per week by 2027. While the comeback mirrors the historic campaign, experts note aging facilities elsewhere and a growing debate among bioethicists about using genetic modification to wipe out the species, a method not yet ready for deployment.
A New Haven startup, Bexorg, uses BrainEx to perfuse donated postmortem human brains, keeping cellular activity alive long enough to study how experimental CNS drugs—potential Alzheimer's therapies—behave in real human tissue. While there is no consciousness and safeguards are in place, the method raises ethical questions about life-death boundaries and could improve CNS drug development.
A biotech startup called Bexorg keeps recently donated human brains on its BrainEX life-support system, arguing the preserved brains offer a more realistic testbed for drugs (including Alzheimer’s candidates) than animal models. The brains hover between life and death, show no consciousness, and are dosed with anesthetic; after about 24 hours they’re sliced into hundreds of pieces for analysis. Bexorg aims to process up to 1,600 brains per year, while pharma firms like Biohaven have already used donor brains for drug testing, fueling ethical and philosophical debates over the use of near-living tissue in research.
Canadian entrepreneur Cathy Tie, nicknamed the “Biotech Barbie,” is pursuing openly regulated germline gene editing to prevent inherited diseases through Origin Genomics, after a controversial past with He Jiankui and a string of biotech ventures. She argues for regulator-approved, transparent research and says the field’s progress is inevitable, while critics warn about safety and the ethical implications for future generations. The piece frames her effort against a backdrop of private funding, a race among biotech startups, and the broader debate over embryo editing versus embryo selection.
A Gothamist item claims Vladimir Putin is reportedly overseeing an effort to grow human replacement organs inside mini-pigs, a controversial claim tied to longevity research.
Henrietta Lacks’ estate has scored another legal win in the decades-long fight over the unauthorized use of her immortal HeLa cells, with recent settlements against major pharma firms following earlier deals (including Thermo Fisher) and ongoing discussions about patient consent and exploitation in medical research.
The family of Henrietta Lacks has reached a second confidential settlement with Novartis over profits from her immortal HeLa cells, continuing a long fight for compensation; terms are undisclosed and follow a prior settlement with Thermo Fisher, underscoring ongoing ethical questions about consent and the benefits derived from her cells.